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ABSTRACT 
Objective: Selection of oral anticoagulants (OACs) in patients with thromboembolic diseases is complex and equivocal in nature, owing majorly to 
the non-adherence to standard clinical guidelines. Moreover, there is a scarcity of data on utilisation pattern of OACs in Indian population. Our 
primary objective was to analyse the prescribing pattern of OACs among in-patients with thromboembolic disorders. The secondary objective was 
to determine the significant predictors that affect their utilisation pattern. 
Methods: This prospective observational study examined the clinical data over 6 mo from in-patients on oral anticoagulation with warfarin and 
acenocoumarol. Patients were recruited into 2 study groups: coronary artery disease (CAD) and non-CAD to analyse the prescription pattern. 
Potential predictors of utilisation pattern were evaluated for significance with logistic regression analysis for CAD group. 
Results: Prescription analysis highlights preference of acenocoumarol (72.4%) over warfarin among 232 in-patients in the study. Lack of 
achievement of target international normalised ratio (INR) levels was noticed in 74.2% of the study population. 57.8% of cases belonged to CAD 
group (males 76.7%; mean age 59.4±13.5 y). Valvular heart disease (VHD) was the significant predictor (p =0.001) of warfarin utilisation among 
CAD patients while male gender, heart failure (HF) and arrhythmia were significant for acenocoumarol. 
Conclusion: Predominance of age<60 y and male gender was observed in the study. Acenocoumarol was preferred over warfarin in all the in-
patient departments. VHD, male gender, HF and arrhythmia significantly affected the OAC utilisation. 
Keywords: Prescribing pattern, Oral anticoagulants, International normalised ratio, Drug-drug interactions 




Anticoagulants (AC) are vital lifesaving drugs used to prevent as well 
as treat arterial, venous and intra-cardiac thromboembolic events [1]. 
As per the Global burden of disease study in India, coronary artery 
disease (CAD) is the main cause of cardiovascular diseases (CVDs) 
accounting for 35% of the disease burden [2]. The pharmacotherapy 
with the oral anticoagulants (OACs) are recommended for long-term 
thromboprophylaxis in patients at high risk of thrombotic 
complications. Also, OACs are observed to reduce the risk of atrial 
fibrillation (AF) complicating to stroke up to two thirds [3]. 
In India, the vitamin K antagonists (VKAs; warfarin and 
acenocoumarol) are the most prevalent choices, in spite of their 
narrow therapeutic index and interindividual treatment response 
variability, majorly due to the ease developed by the physicians after 
years of its usage. Henceforth, the dosage tapering and 
individualization of dose are vital for VKAs [4, 5]. 
Therapeutic management of thromboembolic disorders is often 
based merely on the clinical judgement of a prescriber, regardless of 
the availability of standard guidelines. Furthermore, the interplay of 
comorbidities and several concomitant drugs (polypharmacy), affect 
the efficacy of anticoagulation to a great extent [2]. 
Under and over-anticoagulation are the two major complications 
associated with anticoagulant use, which may lead to the risk of 
thrombosis and haemorrhage respectively. The aim of OAC therapy is 
to maintain an international normalised ratio (INR) of 2-3, which 
provides the best balance between the prevention of thromboembolic 
events and the occurrence of bleeding complications [6]. Therefore, 
monitoring of coagulation parameters and drug levels is a major 
concern due to lack of laboratories with standardised measurement, 
especially in ambulatory patients on AC use.  
The rationale for conducting this study is the scarcity of Indian data 
on the pattern of anticoagulant use, monitoring and achievement of 
target INR. Our study aimed to analyse the prescribing pattern of 
OACs in a South-Indian tertiary care hospital and evaluate the effect 
of various predictors on the drug utilisation. 
MATERIALS AND METHODS 
Study setting and data collection procedure 
The study was conducted for a period of six months in the departments 
of cardiology, neurology and vascular surgery at a tertiary care hospital 
that caters health care services to patients in and around Bengaluru. It 
was a prospective observational study approved by the Institutional 
ethical committee ECR/215/Inst/Ker/2013. The study included patients 
of both gender and more than 18 y of age, treated with one or more 
OACs (acenocoumarol and warfarin). Pregnant women, patients on 
haemodialysis and those on other anticoagulants were excluded. 
The data were collected from medication chart, case sheets, patient’s 
previous medical records and prescriptions, laboratory investigation 
report and medication history interview forms. The data were evaluated 
for the prescribing pattern of OACs and drug-drug interactions (DDIs). 
The patients were categorised into CAD and non-CAD group based on 
their diagnosis according to the International classification of diseases 
version-10 (ICD-10), using data acquired from clinical manifestations, 
ECG changes, Echocardiography/angiography, Doppler findings and 
other laboratory investigations [7]. The study also investigated the 
significant predictors of OAC utilisation based on the demographic and 
clinical characteristics in CAD group. The severity of DDIs was 
categorised as major, moderate and minor using Micromedex® 
Solutions 2016 Truven Health Analytics LLC. Interactions were also 
classified as pharmacokinetic and pharmacodynamics interactions. 
Statistical analysis 
IBM statistical package for the social science version 20.0 (SPSS 
software) was used to generate graphs and data analysis.  
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Descriptive analysis (mean±SD) was used to determine numerical 
variables in the study population. The chi-square test was used to 
analyse the association between different variables in CAD and non-
CAD groups. Univariate logistic regression analysis was used to 
define the predictors of utilisation pattern in the CAD group treated 
with warfarin or acenocoumarol, which were later confirmed using 
multivariate analysis. Variables with p<0.05 were identified as a 
statistically significant predictor of OAC utilisation in CAD patients. 
RESULTS 
Demographics and clinical characteristics 
Among 232 patients, 177 patients (76.3%) were males and the 
majority (N=120; 51.7%) were under the age group of<60 y 
(58.6±15.8 y). 134 (57.8%) patients were diagnosed with CAD and 
98 (42.3%) patients with other conditions, i.e., non-CAD. Patients in 
CAD group were older compared to the non-CAD group (59.5years 
vs. 57.6years; p =0.041). The median length of stay (LOS) in the non-
CAD group was only marginally higher [8 vs. 7.5 d] than CAD. 
However, statistical significance in this regard was not observed (p 
=0.681) [Table-1]. In our study, only 49 (21.1%) patients had a body 
mass index (BMI) within the normal range of 18.5-24.9 kg/m2. On 
the other hand, 108 (46.6%) and 75 (32.3%) patients were obese 
and overweight respectively. 
The pattern of comorbidities among the two study groups-CAD and 
non-CAD depicted hypertension (61.6%) as the most common, 
followed by diabetes mellitus (DM; 47.8 %). Hypertension, DM and 
heart failure (HF) were significantly higher in CAD patients while only 
CVA was significantly higher in non-CAD patients [Table-2]. Valvular 
heart disease (VHD) and arrhythmia were not statistically associated 
with CAD. Among the 232 patients, 65 (28%) had a previous history of 
Percutaneous Transluminal Coronary Angioplasty (PTCA) and 
37(16%) had undergone Coronary Artery Bypass Grafting (CABG). 
 
Table 1: Baseline characteristics of patients with CAD and non-CAD 




























Median LOSc; days 8 (6-11) 7.5 (5-10) 8 (6-11) 0.681 
Past surgical history;  
n (%) 
84 (36.2) 58 (43.3) 26 (26.5) 0.757 
*p<0.05 is considered statistically significant (Chi-square test), Data are given as aNumber (n) of patients with percentages (%) in parentheses or 
as,b mean±standard deviation or as, C Median with the interquartile range in parentheses. 
Abbreviations: CAD (Coronary Artery Disease); LOS (Length of Stay); Non-CAD (Non-Coronary Artery disease). 
 
Table 2: Common comorbidities among CAD and non-CAD patients 
Comorbidities Totala n=232(100%) CADa n=134(57.75%) Non-CADa n=98(42.24%) p-Value* 
Hypertension 143 (61.6) 87 (65) 56 (57.1) 0.034 
DM 111 (47.8) 61 (45.5) 50 (51) 0.000 
Heart failure 61 (26.3) 42 (31.3) 19 (19.4) 0.000 
VHD 22 (9.5) 20 (14.9) 2 (2) 0.294 
Arrhythmia 24 (10.3) 22 (16.4) 2 (2) 0.345 
CVA 17 (7.3) 5 (3.7) 12 (12.2) 0.001 
*p<0.05 considered statistically significant (Chi-square test), aData are given as number (n) of patients with percentages (%) in parentheses., 
Abbreviations: CVA (Cerebrovascular Accident); DM (Diabetes mellitus); VHD (Valvular Heart Disease). 
 
The pattern of duration of OAC therapy depicts that the majority of 
the population (n= 119; 52.3%) were treated for 5-10 d during their 
hospital stay and the mean duration of therapy with OACs was 
calculated to be 5.39±2.78 d. 44% of patients were treated for<5 d 
while a low proportion of 4.7% patients were administered with 
OACs for>10days. However, the duration of therapy largely depends 
on the diagnosis of individual patients and disease severity. 
Utilisation pattern of OACs among CAD and non-CAD patients 
Acenocoumarol (n= 168;72.4%) was preferred over warfarin 
(N=64;27.6%) in our study scenario and in all the three departments 
under study [fig. 1]. Utilisation pattern of acenocoumarol was 
observed to be higher than warfarin in CAD (65.7% vs. 34.3%) and 
non-CAD (81.6% vs.18.3%) patients. 
 
 
Fig. 1: Shows utilisation pattern of acenocoumarol and warfarin in each department under study 
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Determinants of utilisation of OACs in CAD patients 
Application of univariate analysis in patients on warfarin identified 
that age<60 y [p=0.042; 2.681 (1.283-3.360)] and VHD [p=0.003; 
2.190 (0.801-5.99)] were significant predictors of warfarin use. It 
was observed that patients with<60 y were 2.681 times more likely 
to be on warfarin than the elderly. Whereas, multivariate analysis 
established that VHD was the only significant predictor of warfarin 
which elevated its utilisation by 1.55 times (p=0.001). Male gender 
(p=0.038), HF (p=0.016) and arrhythmia (p=0.005) significantly 
increased the utilisation of acenocoumarol use by 1.61, 1.714 and 
2.20 times respectively [table 3]. Multivariate analysis confirmed the 
significance of predictors for acenocoumarol use, derived as per the 
univariate analysis. Male gender (p=0.022), HF (p<0.0001) and 
arrhythmia (p=0.001) increased acenocoumarol utilisation 
correspondingly by 1.92, 1.851 and 1.71 times [table 4]. 
 




n (%) p-Valuec OR (95% CI)a n (%) p-Valuec OR (95% CI)a 
Sex  0.48 1.370(0.572-3.283)  0.038 1.610(1.03-2.530) 
Male (103) 37 (35.9)   66 (64)   
Female (31) 9 (29)   22 (21.4)   
Age  0.042 2.681(1.283-3.360)  0.188 0.614(0.298-1.268) 
<60 (71) 27 (38)   44 (62)   
>60 (63) 19 (30)   44 (70)   
Hypertension (87) 32 (36.8) 0.234 0.626(0.289-1.354) 55 (63.2) 0.32 1.598(0.789-3.459) 
Diabetes Mellitus (61) 25 (41) 0.148 0.582(0.283-1.194) 36 (59) 0.14 1.720(0.838-3.530) 
Heart Failure (42) 19 (45.2) 0.162 0.586(0.274-1.242) 23 (54.8) 0.016 1.714(0.805-3.649) 
VHD (20) 12 (60) 0.003 2.190(0.801-5.99) 8 (40) 0.142 4.558(1.670-2.441) 
Arrhythmia (22) 4 (18.2) 0.448 1.481(0.537-4.087) 18 (81.8) 0.005 2.20(1.21-4.01) 
CVA (5) 3 (60) 0.241 0.776(0.125-4.820) 2 (40) 0.786 1.288(0.207-7.995) 
aOR (95% CI): unadjusted odds’ Ratio with 95% confidence interval, bWarfarin: includes patients treated with warfarin; Acenocoumarol: includes 
patients treated with acenocoumarol, Data are given as number (n) of patients with percentages (%) in parentheses, cp<0.05 is considered as 
statistically significant, Abbreviations: CVA (Cerebrovascular Accident); DM (Diabetes mellitus); VHD (Valvular Heart Disease). 
 
Table 4: Multivariate analysis of warfarin and acenocoumarol utilisation pattern in CAD patients 
Variable Warfarinb Acenocoumarolb 
p-Valuec OR (95% CI)a p-Valuec OR (95% CI)a 
Sex 0.693 1.245(0.420-3.694) 0.022 1.92(1.402-2.52) 
Heart failure 0.164 0.540(0.227-1.287) <0.0001 1.851(0.777-4.411) 
VHD 0.001 1.55(0.520-4.590) 0.862 1.701(0.677-4.314) 
Arrhythmia 0.135 2.835(0.722-11.131) 0.001 1.71(1.30-1.81) 
aOR (95% CI): adjusted odds’ Ratio with 95% confidence interval, bWarfarin: includes patients treated with warfarin; Acenocoumarol: includes 
patients treated with acenocoumarol, cp<0.05 is considered as statistically significant, Abbreviations: VHD (Valvular Heart Disease). 
 
Monitoring pattern and achievement of target INR level  
It was found that most of the patients’ INR was in sub-therapeutic 
range, i.e. INR<2 (N= 141; 60.8%). Merely, 4.7% (N=11) achieved 
target INR, while 13.4% of the overall patients attained supra-
therapeutic level (>3) [fig. 2]. The pattern of INR monitoring 
frequency indicates that 21.1% (n= 49) of the study population was 
not advised for INR monitoring before initiation of VKA therapy. 
 
 
Fig. 2: Pattern of INR according to therapeutic range 
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Fig. 2 shows the pattern of INR levels in the patients under study 
categorised according to therapeutic INR range (2-3). It also depicts 
the percentage of patients in whom INR monitoring was not adviced.  
Abbreviation: INR (International Normalised Ratio) 
Prescription analysis for DDIs 
A total of 192 and 330 potential DDIs were found with warfarin and 
acenocoumarol respectively. The pattern of potential DDIs with 
warfarin revealed 39.6% of major interactions predominantly with 
aspirin (17.7%). There were 25 (26%) moderate interactions found 
with certain antibiotics such as azithromycin, cefoperazone etc. Also, 
34.4% of minor interactions were observed with commonly used 
drugs like atorvastatin, furosemide, etc. There were 45.5% of major 
interactions observed with acenocoumarol, majorly with aspirin 
(17.6%), 17% of moderate interactions were found with drugs like 
dexamethasone, esomeprazole etc. and minor interactions of 37.6% 
were also observed. There were 16.84% of pharmacokinetic and 
46.4% of pharmacodynamic DDIs with acenocoumarol. 
DISCUSSION 
The pattern of hospital admissions for thromboembolic disorders in 
our study setting demonstrates a significant predominance of male 
gender and age<60 y. Previous studies have reported an increased 
incidence of risk factors in this age group which reinforces that 
onset of cardiovascular disorders occurs at an early age [8, 9]. 
Furthermore, epidemiological studies conducted in younger 
population indicate that the risk of developing cardiac disorders was 
higher in male (49%) than in the female (32%) group [10]. The 
majority of the patients were either obese or overweight (78.9%, 
p<0.0001) which is analogous to a previous study [11]. This 
establishes the notion that obesity is a major predisposition for 
thromboembolic disorders [8]. 
WHO (2012) stated hypertension as the number one cause of 
mortality and a major risk factor for cardiac diseases and stroke in 
the worldwide [12]. Hypertension, a significant susceptibility factor, 
contributes to about 57% of CAD and 24% of stroke-induced 
mortality in India [13]. In addition, substantially elevated blood 
pressure levels have been observed in younger men than in women 
(27% vs. 12%) [14]. It has also been known that hypertension, being 
a major contributor to thrombotic diseases such as DVT, increases 
the risk by twofold in the young male population [15]. Our study 
provides further evidence to these findings as hypertension was the 
most prevalent comorbid condition in the patients involved in our 
study, similar to the conclusions of other authors [2, 16, 17]. This 
prevalence of thromboembolic disorders could be indicative of the 
increased proportion of obesity, smoking or alcohol consumption 
and sedentary lifestyle among the younger males.  
Our study presented that acenocoumarol was prescribed with a 
greater proportion of 72.4 %, which is in discordance with other 
South-Indian studies [18, 19]. The differences in the usage of these 
drugs may be due to the prescribing preference among physicians in 
our study setting as acenocoumarol has been documented to 
provide steady anticoagulation and has well established a long-term 
safety profile, in spite of its short half-life [20]. However, 
controversies in the drug of choice indicate that comparative 
evaluation of these drugs should be validated in a larger cohort. 
The evaluation of predictors for OAC utilisation among CAD patients 
found that VHD was the sole determinant of warfarin use. However, 
male gender, HF and arrhythmia were significant for 
acenocoumarol. The factors conducive to the preference of 
acenocoumarol in arrhythmia were the increased likelihood of 
bleeding and the higher incidence of a stroke upon treatment with 
warfarin. Several drug utilisation studies have contradicted the use 
of warfarin in patients with arrhythmia especially AF, due to these 
research outcomes and thereby indicate the inappropriateness of 
warfarin use for the pharmacological management of arrhythmic 
patients [21].  
Acenocoumarol provides better stability of coagulation parameters 
in geriatrics, owing to their increased intrinsic sensitivity to OACs 
upon aging. Hence, prescribers do not prefer the use of warfarin in 
the elder population due to its relatively poor maintenance within 
the therapeutic INR range [22]. Warfarin utilisation was 2.681 times 
more preferred in age<60 y (p =0.042). On the other hand, 70% of 
the elderly were treated with acenocoumarol, despite the lack of 
statistical significance. 
In our study, only a mere percentage of 4.7 achieved these levels. 
The difficulty to maintain INR within the narrow therapeutic range 
has already been established. This may be due to its interactions 
with food and concomitant drugs, a dearth of patient cooperation 
and genetic causes, which further complicate the achievement of 
target INR levels [23]. In a study of warfarin utilisation, most of the 
patients (73%) on OACs were within the therapeutic INR range of 2-
3 [11]. The American College of Chest Physicians (ACCP) Evidence-
Based Clinical Practice Guidelines-9th edition, suggest weekly INR 
testing in patients during initiation of VKA therapy [24]. In our study 
population, this stringent practice of weekly INR monitoring was 
observed in 21.2% of the cases which may be due to economic 
burden. This deficiency of INR monitoring should be addressed by 
physicians in India in order to prevent the incidence of bleeding 
among anticoagulated patients. 
VKAs, due to their high plasma protein binding, CYP450 dependent 
metabolism and narrow therapeutic index escalate the potential risk 
of fatal interactions with concomitant drugs, prescribed for the 
management of various cardiovascular complications [25]. Nearly 
half of the study population had major DDIs, collectively for warfarin 
and acenocoumarol similar to other studies in Indian population. 
Pharmacodynamic interactions were estimated to be 70.9%, which 
was only slightly higher than the estimates of Singh V et al. [26] 
(65.7%). Furthermore, acenocoumarol was the most commonly 
identified drug with interactions, which is also parallel to our 
findings. However, its over-utilisation in our study population could 
have possibly contributed to this indictment against acenocoumarol. 
The studied OACs were majorly interacting with antiplatelet drugs 
i.e., aspirin followed by clopidogrel which was similar to the prior 
studies [25, 27]. Aspirin and several NSAIDs (Non-steroidal anti-
inflammatory drugs) exhibit their pharmacological actions via 
inhibition of Cyclo-oxygenase enzyme, thereby preventing the 
conversion of arachidonic acid to prostaglandins. Consequently, the 
formation of thromboxane A2 in platelets is inhibited followed by 
prevention of thrombus formation. Upon concomitant 
administration of these drugs with anticoagulants, synergistic effect 
incline towards the increased haemorrhagic complications. 
Furthermore, pharmacokinetic DDIs occurs when such drugs 
compete for binding sites of warfarin and/or acenocoumarol [28]. 
The study also found DDIs with antibiotics such as azithromycin, 
cefoperazone etc. similar to Teklay G et al. [27]. Screening of drug 
interactions of OACs with concomitant medications is decisive, as it 
hinders the achievement of the therapeutic outcome. 
LIMITATION 
The study was carried out only for a short duration and was 
restricted to two oral anticoagulants-acenocoumarol and warfarin. 
One of the major limitations of our study was the failure to examine 
the confounding factors such as diet pattern, socioeconomic status, 
which could have influenced the significance of various factors on 
the utilisation pattern. The impact of OACs in patients with supra-
therapeutic INR levels could not be assessed due to the lack of 
feasibility of laboratory facilities for serum drug level analysis. 
CONCLUSION 
Acenocoumarol was preferred over warfarin, in all the three 
departments where the study was carried out. The predominance of 
male gender and age<60 y were observed among patients diagnosed 
with thromboembolic disorders. Our study highlights the need for 
achieving target INR levels and adherence to current guidelines with 
regard to the frequency of monitoring in anticoagulated patients. 
Maintenance of therapeutic INR levels is crucial for successful 
pharmacological management of thromboembolic disorders, 
preventing the occurrence of haemorrhagic events. Evaluation of 
determinants provides insight into the influence of patient-specific 
factors such as demographics and clinical comorbidities on the OAC 
utilisation pattern. 
Jeny et al. 
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